Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
Complete regulatory breakdown of Jatenzo (oral testosterone undecanoate), including its FDA approval history, prescribing label specifics, compounding legal status under federal law, and what patients and clinicians need to know about access.
Read clinical reviewA detailed comparison of how the FDA and EMA evaluated oral testosterone undecanoate (Jatenzo), including approval timelines, label requirements, cardiovascular risk language, and post-market surveillance obligations.
Read clinical reviewA detailed review of Jatenzo (oral testosterone undecanoate) FAERS safety signals, FDA label warnings, post-market surveillance data, and clinical guidance for prescribers and patients.
Read clinical reviewA complete regulatory history of Jatenzo (oral testosterone undecanoate), covering FDA approval in 2019, label requirements, REMS status, and post-market safety surveillance through 2024.
Read clinical reviewA complete guide to Jatenzo (oral testosterone undecanoate) regulatory history: FDA approval date, REMS program, black-box warnings, labeling requirements, and post-market surveillance data.
Read clinical reviewA comprehensive timeline of every FDA label change to Jatenzo (oral testosterone undecanoate) from initial approval through 2026, including REMS requirements, cardiovascular warnings, and dosing revisions.
Read clinical reviewA clinical review of Jatenzo (oral testosterone undecanoate) covering its FDA approval history, patent litigation, labeling requirements, REMS considerations, and ongoing legal challenges facing Tolmar.
Read clinical reviewA clinical review of Jatenzo (oral testosterone undecanoate), its FDA approval history, current label, post-market safety data, and the next-generation oral TRT pipeline.
Read clinical review